Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
PROPYLTHIOURACIL (UNII: 721M9407IY) (PROPYLTHIOURACIL - UNII:721M9407IY)
NCS HealthCare of KY, Inc dba Vangard Labs
PROPYLTHIOURACIL
PROPYLTHIOURACIL 50 mg
ORAL
PRESCRIPTION DRUG
Propylthiouracil is indicated in the medical treatment of hyperthyroidism. Long-term therapy may lead to remission of the disease. Propylthiouracil may also be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy. Propylthiouracil is also used when thyroidectomy is contraindicated or not advisable. Propylthiouracil is contraindicated in the presence of hypersensitivity to the drug or any of the other product components and in nursing mothers because the drug is excreted in milk.
50 mg — Each white, round, tablet imprinted with on one side and 348 and partial bisect on the other side contains 50 mg of Propylthiouracil, USP. Tablets are supplied in blisterpacks of 30 (NDC 0615-7583-39).
Abbreviated New Drug Application
PROPYLTHIOURACIL- PROPYLTHIOURACIL TABLET NCS HEALTHCARE OF KY, INC DBA VANGARD LABS ---------- PROPYLTHIOURACIL TABLETS, USP 40-8756 REVISED – JANUARY 2008 RX ONLY DESCRIPTION Propylthiouracil (6-propyl-2-thiouracil) is one of the thiocarbamide compounds. It is a white, crystalline substance that has a bitter taste and is very slightly soluble in water. Each tablet contains propylthiouracil, 50 mg (293.7, µmol), lactose monohydrate, corn starch, colloidal silicon dioxide, povidone, pregelatinized starch, and magnesium stearate. Propylthiouracil is an antithyroid drug administered orally. The molecular weight is 170.23. The molecular formula is C H N OS, and the structural formula is as follows: CLINICAL PHARMACOLOGY Propylthiouracil inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection. Propylthiouracil is readily absorbed from the gastrointestinal tract. It is metabolized rapidly and requires frequent administration. Approximately 35% of the drug is excreted in the urine, in intact and in conjugated forms, within 24 hours. In laboratory animals, various interventions, including propylthiouracil administration, that continuously suppress thyroid function and thereby increase TSH secretion result in thyroid tissue hypertrophy. INDICATIONS AND USAGE Propylthiouracil is indicated in the medical treatment of hyperthyroidism. Long-term therapy may lead to remission of the disease. Propylthiouracil may also be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy. Propylthiouracil is also used when thyroidectomy is contraindicated or not advisable. CONTRAINDICATIONS Propylthiouracil is contraindicated in the presence of hypersensitivity to the drug or any of the other product components and in nu Lue koko asiakirja